Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy
A prodrug is bioreversible medication that is specifically converted to the active drugs by enzymes overexpressed in the tumor microenvironment, which can considerably reduce the chemotherapy-induced side effects. However, prodrug strategies usually have low antitumor efficacy compared to free drugs...
Saved in:
Main Authors: | Hanhee Cho (Author), Man Kyu Shim (Author), Yujeong Moon (Author), Sukyung Song (Author), Jinseong Kim (Author), Jiwoong Choi (Author), Jeongrae Kim (Author), Youngjoo Lee (Author), Jung Yeon Park (Author), Yongju Kim (Author), Cheol-Hee Ahn (Author), Mi Ra Kim (Author), Hong Yeol Yoon (Author), Kwangmeyung Kim (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy
by: Hanhee Cho, et al.
Published: (2021) -
Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy
by: Youngjoo Lee, et al.
Published: (2024) -
Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses
by: Jeongrae Kim, et al.
Published: (2022) -
Nano-Delivery of Immunogenic Cell Death Inducers and Immune Checkpoint Blockade Agents: Single-Nanostructure Strategies for Enhancing Immunotherapy
by: Yujeong Moon, et al.
Published: (2024) -
Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death
by: Yongwhan Choi, et al.
Published: (2020)